Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext:IPN;
ADR:IPSEY), today announced that the U.S. Food and Drug Administration
(FDA) has accepted for review its supplemental Biologics License
Application (sBLA) for Dysport ® (abobotulinumtoxinA) for the
treatment of upper limb spasticity in adult patients.
for Ipsen Biopharmaceuticals, Inc. Announces FDA Acceptance of Filing for Dysport® (abobotulinumtoxinA) in the Treatment of Upper Limb Spasticity in Adult Patients investment picks